Sanofi SA (ADR) (SNY), Merck & Co., Inc. (MRK): Healthier Days Loom as 3 Big Pharmas Move on Dengue Shots

Page 1 of 2

Mosquito bites sure suck, literally and figuratively. But more so if these are delivered by the insects’ female species, which cause viral infections. But forget malaria. It is dengue fever, also known as hemorrhagic fever, which now ranks as the world’s most virulent mosquito-borne viral disease, says the World Health Organization. Some 3 billion people in 100 countries, or roughly half of mankind, are estimated to be at risk of this disease, the incidence of which has grown 30-fold during the last 50 years.

Poised for gains from brewing remedies

The good news is, in about two years, the world will possibly have its first dengue vaccine. The big pharma Sanofi SA (ADR) (NYSE:SNY) is now conducting two late-stage human testings involving some 45,000 participants in Asia and Latin America. The results are expected either late 2013 or in 2014.

In addition, there are other vaccine types in the most advanced stage of development. Phase I trial, for instance, has been completed on a vaccine developed by the privately held Hawaii Biotech. New Jersey-based Merck & Co., Inc. (NYSE:MRK) now owns the rights on this vaccine, which it acquired in 2010.

The U.K.-based GlaxoSmithKline plc (ADR) (NYSE:GSKis also in pursuit of a vaccine type similar to Sanofi SA (ADR) (NYSE:SNY)’s. It has conducted several clinical studies on this vaccine, including those done in the U.S., Puerto Rico, and Thailand. The company has also partnered with the Fiocruz, a Brazilian foundation, for the development and manufacturing of the vaccine for dengue in Brazil where this disease is a major health concern.

A prop-up for a weak quarter

Sanofi SA (ADR) (NYSE:SNY)An advance in Glaxo’s pursuit of a dengue vaccine should provide tailwinds to the company, which has been reaping some negative market sentiment due to a recent bribery scandal in China and generics eating into its market share. Reporting a 4% core EPS gain on 2% sales growth in the second quarter, Glaxo acknowledged that the result of the bribery investigation is likely to impact its subsequent performance in China.

Certainly, a step up of the dengue vaccine in Merck & Co., Inc. (NYSE:MRK)’s pipeline can also burnish this company’s allure among investors who were turned off recently by a staggering 48% drop in company earnings and 10% decline in revenue during the second quarter primarily due to competition from generics.

Like Glaxo and Merck & Co., Inc. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY) has also been feeling the pinch of generic competition. In the second quarter, sales lost to generics resulted in a 6.3% decline in Sanofi’s total sales and an 18.5% drop in business EPS.

Despite their recent weak results, a strong rebound from this triumvirate can’t be discounted. Besides their dengune vaccines under development, they also have other drugs in the pipeline which are potential earning catalysts.

For the near term, Merck & Co., Inc. (NYSE:MRK) hopes to draw strength from about 40 drugs in its pipeline, out of which six are close to market launch. Just this July, the U.S. FDA has accepted the new drug application for Merck’s anti thrombotic candidate, vorapaxar, for standard testing. Speculations are also rife that the company is eyeing to bolster its product entries in the lucrative oncology medicines through an acquisition.

GlaxoSmithKline plc (ADR) (NYSE:GSK), for its part, flaunts new respiratory products coming onto the market, one of which is the recently FDA-approved Breo Ellipta, which analysts believe to have a peak potential of $1.3 billion sales in the U.S. alone. Likewise potent in earnings possibility is the company’s protein-based therapy, ofatumumab, for multiple sclerosis, now on Phase II trial.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 44 percentage points in 21 months Learn how!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!